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Summary Two open, phase 11 studies were performed to evaluate the activity and toxicity of infusional topotecan in patients with advanced
non-small-cell lung carcinoma (NSCLC) and advanced breast cancer who had not received previous chemotherapy for metastatic disease.
Twenty-five patients with an ECOG performance score < 2 were treated with infusional topotecan administered as a daily, continuous
intravenous infusion starting at 0.6 mg m-2 day-' (NSCLC) and 0.5 mg m-2 day-1 (breast cancer) for 21 days every 4 weeks. Three patients
achieved a partial response as defined by WHO criteria: one with NSCLC (8%; 95% Cl 0-39%) and two with advanced breast cancer
(15%; 95% Cl 2-45%). The major toxicities were neutropenia and thrombocytopenia, with one episode of neutropenic sepsis. These data
suggest that topotecan delivered as a continuous intravenous infusion over 21 days as single-agenttherapy does not appearto offer a clinical
advantage over conventional 5-day schedules against advanced NSCLC and advanced breast cancer.
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In advanced non-small-cell lung cancer (NSCLC), few conven-
tional chemotherapeutic agents have single-agent activity in
excess of 15% (Lilenbaum and Green, 1993). In selected patients,
current combination chemotherapy regimens yield response rates
of up to 40%, survival benefit is modest (Hopwood et al, 1995)
and symptom control can be achieved in over 50% (Ellis et al,
1995). First-line chemotherapy regimens for metastatic breast
cancer extend median survival by 9-12 months. Second-line
chemotherapy regimens have an objective response of 25-50%
with a median time to progression of 4-6 months. In both tissue
types, more effective new agents are needed.
Topotecan is a semisynthetic, water-soluble analogue of camp-
tothecin and acts by inhibiting the function oftopoisomerase I, an
essential enzyme involved in maintaining DNA structure (Burris
et al, 1992). Active clinical research is under way, aimed at
defining the role that topotecan may have to play in the manage-
ment ofovarian, lung and breast cancer, whether as a single agent
or in combination with established chemotherapy regimens
(Lynch, 1996). The mechanism of action of topotecan suggests a
theoretical advantage for delivery as a continuous infusion. With
24-h exposure, schedule-dependent cytotoxicity for topotecan was
reported with a steep concentration-response curve and no plateau
(Cheng et al, 1994). Clinical studies have investigated topotecan
delivered as a continuous infusion over various time schedules
(Lynch, 1996). In studies investigating 30-min intravenous infu-
sions, topotecan was given daily for 5 consecutive days every
3 weeks to patients with advanced solid malignancies at doses
ranging from 0.5 to 2.5 mg m-2 day-'. Neutropenia was the dose-
limiting toxicity, and 1.5 mg m-2 was the recommended starting
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dose oftopotecan for pretreated patients, with potential escalation
to 2.0 mgm-2. Responses wereobserved inpatients with small-cell
lung carcinoma, non-small-cell lung carcinoma, pancreatic cancer
and platinum-refractory ovarian carcinoma (Eckardt et al, 1992;
Rowinsky et al, 1992; Saltz et al, 1993; Verweij et al, 1993). A
phase I trial of low-dose continuous infusional topotecan in
heavily pretreated patients reported objective responses with
ovarian cancer, breast cancer and non-small-cell lung cancer. The
dose-limiting toxicity was myelosuppression, with thrombo-
cytopenia greater than neutropenia, seen at a dose level of
0.70 mg mi-2 day-' administered as a continuous 21-day infusion
every 28 days (Hochster et al, 1994). Of 21 platinum-pretreated
ovarian cancer patients receiving continuous 21-day infusional
topotecan at a starting dose of 0.4 mg in-2 day-', nine patients
responded (43%), including one complete responder (5%). Seven
patients (33%) had grade 3 leucopenia and one patient (5%) grade
3 thrombocytopenia (Hochster et al, 1996). We have performed an
open-label phase II trial of continuous, intravenous infusional,
ambulatory topotecan in patients with advanced NSCLC and
advanced breast cancer who have not received previous chemo-
therapy for metastatic disease.
The aim of this trial was to test the hypothesis that infusional
topotecan might have superior activity to conventional schedules.
Preliminary data supporting this hypothesis wouldjustify a subse-
quent largerandomized phase III trial comparing the two schedules.
MATERIALS AND METHODS
Patients
Patients presenting to the Royal Marsden Hospital and St
Bartholomew's Hospital from March 1994 to March 1995 were
entered into the study if they fulfilled the following criteria: histo-
logical orcytological diagnosis ofmalignancy; measurable orevalu-
able stage I1IB/IV NSCLC or stage IV breast adenocarcinoma;
1636Infusional topotecan in non-small-cell lung andbreastcancer 1637
performance status < 2 (ECOG-WHO scale); full blood count and
biochemistry as follows: haemoglobin3 9.0 g dl-1 (after transfusion
if needed); WBC 3.5 x 109 mm-3; granulocytes 1.5 x 109 mm-3;
platelets 100 x 10-3 mm-3, creatinine 130 ,umol 1-1; serum bilirubin
35 imol 1-1; AST, ALT and alkaline phosphatase twice the upper
limit of normal if liver metastases were absent by abdominal
computerized tomography (CT) or MRI scan or five times the
upper limit of normal if liver metastases were present and life
expectancy 3 months.
Patients were excluded ifthey had a significant history ofinter-
current disease, previous malignancy, CNS metastases or previous
chemotherapy. Patients with breast cancer were permitted expo-
sure to radiotherapy for bony metastases if the study indicator
lesions were outside the radiotherapy field. All patients provided
signed, informed consent and the study was approved by the
institutional ethics committees.
Treatment
Patients commenced topotecan for advanced NSCLC at 0.6 mg
m-2 day-' and for advanced breast cancer at 0.5 mg m-2 day-'
administered by continuous intravenous infusion for 21 days every
4 weeks. In the phase I study of heavily pretreated patients, the
maximum tolerated dose was 0.53 mg m-2 day-' (Hochster et al,
1994). The starting doseoftopotecan in the patients with advanced
breast cancer was lower than that of the lung cancer patients
because of previous exposure to marrow toxic treatments
combined with the expected haematological toxicity of topotecan
therapy. In July 1994, a dose adjustment was made for all patients,
reducing the starting dose by 0.1 mg m-2 day-' because of
prolonged myelosuppression noted in other patient groups
receiving topotecan and affecting the first three NSCLC and seven
breast cancer patients. Haematological growth factors were not
used in this study. Patients were assessed for response after two
cycles oftherapy and in the absence of severe toxicity and in the
setting of at least stable disease they could receive further treat-
ment to a maximum ofsix cycles.
Response assessment, toxicity and dose modifications
Response assessment was according to standard WHO criteria
(Miller etal, 1981). Toxicity was assessed by standard CTC criteria
(National Cancer Institute, 1981). Duration of response and
survival were calculated from date of randomization until date of
relapse or censor. Full blood counts were performed on days 8, 15
and 22 and serum chemistry performed on days 8 and 22 of each
treatment cycle. Topotecan therapy was stopped immediately if
patients experienced any grade 4 symptom toxicity and the dose of
the next course was reduced by 0.1 mg m-2 day-' ifpatients experi-
enced grade 4 neutropenia during the course or grade 2 thrombocy-
topenia lasting beyond day 28 of the treatment course. The
minimum infusional dose was two dose level reductions; at that
stage the patient was withdrawn from study. The topotecan dose
was increased by 0.1 mg m-2 day-' ifduring the previous course no
toxicity greater than grade 2 and no dose delay was experienced.
Statistics
Interim analysis was planned at the first stage using Gehan's
method for phase II trials (Gehan, 1961).
Table 1 Patient characteristics
Lung Breast
Sex (n) (n)
Male 10 0
Female 2 13
Age
Range 39-65 years 40-73 years
Median 46 years 50 years
Performance status
ECOG 0 2 6
ECOG 1 10 7
Stage
IIIB 5 (42%) LABC 1 (8%)
IV 6 (50%) Inflammatory 1 (8%)
Relapse 1 (8%) Relapse 11 (84%)
Histology
Adenocarcinoma 6 (50%) IDC 10 (77%)
Large 2 (17%) Squamous 1 (7%)
Squamous 3 (25%) FNA only 2 (16%)
Other 1 (8%)
Metastatic Sites
Local 6
Regional LN 5
Adrenal 3
Bone 2 5
Liver 4 3
Lung 3
Distant LN 3 4
Pleura 3
Pleural effusion 1
Soft tissue
(n), Number of patients; IDC, invasive ductal carcinoma; LABC, locally
advanced breast cancer; FNA, fine-needle aspirate.
RESULTS
Patient characteristics
Twenty-five patients (12 with NSCLC and 13 with breast cancer)
were entered into the studies and their characteristics are shown in
Table 1. The reasons for early stopping of the trial are discussed
below. Of the patients with breast cancer, seven had received
previous preoperative or adjuvant chemotherapy: one primary
epirubicin, cisplatin, 5-fluorouracil; one mitoxantrone,
methotrexate, mitomycin-C; and five adjuvantcyclophosphamide,
methotrexate, 5-fluorouracil chemotherapy. Six patients had
received adjuvant and one patient preoperative tamoxifen,
whereas six patients had received endocrine therapy for metastatic
disease. No patient had received more than one previous
chemotherapy regimen. Patients with advanced NSCLC had not
received previous systemic therapy. Bone marrow biopsy was not
routinely performed before commencing therapy with topotecan.
Patients with known bony disease were evaluable for response at
these sites and bony disease occurred in the context of other
measurable metastatic disease in all cases.
Response
Three ofthe 25 patients responded according to WHO criteria. One
patient with stage IIIB NSCLC had a partial response (8%; 95% CI
0-39%), and two patients with locally advanced/metastatic breast
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Table 2 Haematological and biochemical toxicities
WHO grade (%)
0 1-2 3 4
Haematological
Haemoglobin 3 (12) 17 (68) 4 (16) 1 (4)
WCC 6 (24) 9 (36) 8 (32) 2 (8)
Platelets 12 (48) 6 (24) 3 (12) 4 (16)
Creatinine 24 (96) 1 (4) 0 (0) 0 (0)
Biochemical
SAP 19 (76) 6 (24) 0 (0) 0 (0)
AST 18 (72) 7 (28) 0 (0) 0 (0)
ALT 20 (80) 5 (20) 0 (0) 0 (0)
Bilirubin 21 (84) 4 (16) 0 (0) 0 (0)
cancer had partial responses (15%; 95% CI 2-45%). The patient
with lung adenocarcinoma had apartial response inboth theprimary
and regional lymph nodes assessed on computerized tomography
scans. Ofthe two patients with breast cancer, one patient responded
in the breast, regional and distant lymph nodes and soft tissue sites,
whereas the other patient responded completely in regional lymph
nodes, distant lymph nodes and metastatic soft tissue sites. Fourteen
patients had stable disease with a median duration of 13 weeks for
the seven NSCLC cancer patients and 11 weeks for the seven breast
cancer patients. Five patients with breast cancer went on to receive
conventional chemotherapy and three had partial responses to
therapy, including one ofthe responding patients. The median dura-
tion of survival was 41 weeks (range 17-60+ weeks) for the
advanced NSCLC patients and 52 (range 23-59) weeks for the
advanced breast cancer patients.
Dose modifications, dose delays and toxicity
A total of 80 cycles of topotecan were delivered: 41 cycles in
patients with advanced NSCLC and 39 in patients with advanced
breast cancer. Patients with advanced NSCLC received a median
of3.5 cycles (range 1-6) and patients with advanced breast cancer
received a median of two cycles (range 1-6). The toxicity of
therapy in both patient populations is shown in Tables 2 and 3. The
toxicities of infusional topotecan did not differ markedly between
the two patient groups and so have been combined. Two patients
(8%) suffered from a grade 3 Hickman line infection, associated
with grade 3 neutropenia; three patients (12%) had grade 3 and one
(4%) had grade 4 febrile neutropenic episodes. Three patients
(12%) suffered from grade 3 malaise or grade 3 vomiting. Five
patients (20%) developed significant grade 3-4 anaemia, ten
patients developed (40%) grade 3-4 neutropenia and seven
patients (28%) suffered from grade 3-4 thrombocytopenia with
one episode ofrelated epistaxis. In both patient groups, topotecan
dosing was modified according to toxicity, principally haemato-
logical. Seven patients with advanced NSCLC had a total of 11
increments in topotecan dose, six patients had dose reductions
according to protocol, with ten delays in treatment. Two patients
with advanced breast cancer had two increments in topotecan
dose, four patients had a total of five dose reductions with 12
delays in treatment and one patient stopping therapy because of
neutropenic sepsis. No patients experienced significant renal
dysfunction or hepatic dysfunction and there were no deaths on
treatment.
Table 3 Clinical toxicities
WHO grade (%)
0 1-2 3 4
Alopecia 5 (20) 20 (80) 0 (0) 0 (0)
Constipation 9 (36) 15 (60) 1 (4) 0 (0)
Diarrhoea 18 (72) 7 (28) 0 (0) 0 (0)
Epistaxis 24 (96) 1 (4) 0 (0) 0 (0)
Haematuria 24 (96) 1 (4) 0 (0) 0 (0)
Hot flushes 22 (88) 3 (12) 0 (0) 0 (0)
Infection - Hickman line 15 (60) 8 (32) 2 (8) 0 (0)
Infection - Other 18 (72) 3 (12) 3 (12) 1 (4)
Malaise 4 (16) 18 (72) 3 (12) 0 (0)
Nausea/vomiting 3 (12) 19 (76) 3 (12) 0 (0)
Neuropathy 24 (96) 0 (0) 1 (4) 0 (0)
Skin 23 (92) 2 (8) 0 (0) 0 (0)
Stomatitis 14 (56) 11 (44) 0 (0) 0 (0)
Taste 23 (92) 2 (8) 0 (0) 0 (0)
Transient ischaemic attack 24 (96) 1 (4) 0 (0) 0 (0)
DISCUSSION
The aim ofthis phase II study was to test the hypothesis that infu-
sional topotecan might have activity superior to conventional dose
scheduling based on its mode ofaction. When the trial was started,
minimum response rates of 20% in advanced NSCLC and 30% in
advanced breast cancer were determined to be of clinical interest
in these patient populations. The studies had initially aimed to
accrue a minimum of 9 and 14 patients respectively, and in the
absence of serious adverse events, patient accrual would be deter-
mined by the number ofresponding patients. During the course of
this trial further data emerged, as described below, suggesting that
conventional-schedule topotecan might have greater activity than
early studies had suggested. As these results emerged, it became
clear to us that our own data were entirely failing to support the
hypothesis of increased activity for infusional topotecan. This
factor, coupled with the relative complexity ofdelivering ambula-
tory therapy and the potential complications ofsuch treatment, led
us to terminate this study early based on clinical grounds and both
trials were therefore discontinued after 12 and 13 patients in the
lung and breast cancer studies respectively.
Lynch and colleagues (1994) evaluated topotecan in 20 previ-
ously untreated patients with metastatic NSCLC at the dose of
2 mg m-2 day-I given intravenously for 5 days every 3 weeks. No
clinical responses were seen and patient accrual was halted.
Eleven patients (55%) had stable disease and nine (45%) had
progressive disease when treated with topotecan. Toxicity
included neutropenia and rash. The median survival duration for
all patients was 7.6 months.
In contrast, more encouraging results have emerged from other
groups investigating topotecan using a 5-day schedule. Perez-
Soler andcolleagues (1996) have reported six partial responses out
of 40 assessable (48 registered) patients with advanced NSCLC
treated with topotecan administered as a 30-min i.v. infusion for
S consecutive days at a dose of 1.5 mg m-2 day-'. The authors
report five partial responses in 14 patients (36%) with squamous
cell carcinoma and one partial response in 26 patients with other
histologies (4%) (P = 0.014). The overall median survival was
38 weeks. Grade 3-4 neutropenia and thrombocytopenia occurred
in 76% and 10% of courses, respectively, and seven episodes of
febrile neutropenia were recorded from a total of 184 courses of
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topotecan administered. This group discusses the possibility that
the higher number of patients with squamous-cell histology may
have influenced the difference in response rates reported in their
study and that of Lynch and colleagues (1994). In addition the
higher incidence of grade- 3-4 marrow suppression may reflect a
higher dose intensity that could have influenced response rates
(Perez-Soler et al, 1996).
Weitz and colleagues (1995) have reported in abstract form a
study of78 patients with advanced NSCLC randomized to receive
eithertopotecan administered as a 30-min i.v. infusion on 5 consec-
utive days every 3 weeks at a dose of 1.5 mg m-2 day- I (arm A) or
as a continuous infusion over 3 days every 4 weeks at a dose of 1.3
mg m-2 day-' (arm B). Five partial responses were reported in 38
patients in arm A (13%) and two partial responses in 37 evaluable
patients, from a total of 40, in arm B (5%). The median time to
progression was 106 days for arm A patients and 63 days for arm B
patients with a median overall survival time of252 days for arm A
patients and 179 days forarm B patients. There were no differences
between squamous-cell histology and other histologies. Two cases
ofgrade 3 malaise occurred in both arms ofthe study and one case
ofgrade 4 vomiting in arm A (Weitz et al, 1995).
Chang and colleagues (1995) treated 16 patients of good
performance status and with measurable, metastatic breast cancer
with topotecan 1.5 mg m-2 day-' x 5 every 3 weeks. Five partial
responses, one minor response and three patients with stable
disease were reported in 14 eligible patients. Eight patients suffered
from grade 3-4 neutropenia and one patient died from sepsis.
In conclusion, infusional topotecan is well tolerated with a rela-
tively low incidence ofserious toxicities but with significant bone
marrow suppression. This infusional approach appears, however,
not to offer significant clinical advantage when compared with
other schedules oftopotecan delivery.
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